Vasomedical raises $2.5m:
This article was originally published in Clinica
Executive Summary
Westbury, New York-based Vasomedical has closed a $2.5m round of private financing. It will use the proceeds for marketing efforts relating to the use of its EECP external counterpulsation therapy as treatment for congestive heart failure patients; for activities to expand reimbursement coverage with third-party payers; and for the further promotion of EECP therapy in the current refractory angina market segment. The EECP system is designed as a noninvasive method to increase circulation in the heart and restore systemic vascular function.
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.